Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway.

4区医学 Q3 Medicine

Disease Markers Pub Date : 2023-02-18 eCollection Date: 2023-01-01 DOI:10.1155/2023/7146589

Jie Huang, Xiaoling Fu, Qiang Xue, Peng Ma, Yating Yin, Minjie Jiang, Yunpeng Lu, Qi Ying, Jun Jiang, Hua He, Da Wu

{"title":"Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway.","authors":"Jie Huang, Xiaoling Fu, Qiang Xue, Peng Ma, Yating Yin, Minjie Jiang, Yunpeng Lu, Qi Ying, Jun Jiang, Hua He, Da Wu","doi":"10.1155/2023/7146589","DOIUrl":null,"url":null,"abstract":"Background: The most prevalent malignant tumor in a human brain nervous system is called glioma. Peptide is a compound formed by the peptide bond of α-amino acids, and the development of polypeptide drugs has been widely used in many fields. We plan to investigate the underlying peptides with clinical value in glioma.Method: Based on public databases, we targeted the common genes between glioma differentially expressed genes (DEGs) and peptide genes related to glioma prognosis. Then, these common genes were analyzed by LASSO-Cox analysis, prognostic risk model, and nomogram to identify key prognostic peptide genes and the target gene in this study. Next, the mechanism of target gene in glioma was explored by bioinformatics analysis and functional experiments.Results: We obtained a total of 26 overlapping genes for the following study. After that, 6 independent prognostic factors (REPIN1, PSD3, RDX, CDK4, FANCI, and ARHGEF9) were obtained and applied to construct the prognostic nomogram, and ARHGEF9 was the target gene in the study. Next, peptide ARHGEF9 was found to inhibit glioma cell development. Through Spearman's correlation analysis, ARHGEF9 had a close relation with PI3K/AKT/mTOR pathway. In functional experiments, peptide ARHGEF9 could suppress the protein expressions of p-PIK3K, p-AKT and p-mTOR, while IGF-1 could reverse this effect.Conclusion: This study identifies 6 new prognostic biomarkers for glioma patients. Among them, peptide ARHGEF9 gene is an inhibitory gene functioning by targeting PI3K/AKT/mTOR pathway.","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2023 ","pages":"7146589"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Disease Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/7146589","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The most prevalent malignant tumor in a human brain nervous system is called glioma. Peptide is a compound formed by the peptide bond of α-amino acids, and the development of polypeptide drugs has been widely used in many fields. We plan to investigate the underlying peptides with clinical value in glioma.

Method: Based on public databases, we targeted the common genes between glioma differentially expressed genes (DEGs) and peptide genes related to glioma prognosis. Then, these common genes were analyzed by LASSO-Cox analysis, prognostic risk model, and nomogram to identify key prognostic peptide genes and the target gene in this study. Next, the mechanism of target gene in glioma was explored by bioinformatics analysis and functional experiments.

Results: We obtained a total of 26 overlapping genes for the following study. After that, 6 independent prognostic factors (REPIN1, PSD3, RDX, CDK4, FANCI, and ARHGEF9) were obtained and applied to construct the prognostic nomogram, and ARHGEF9 was the target gene in the study. Next, peptide ARHGEF9 was found to inhibit glioma cell development. Through Spearman's correlation analysis, ARHGEF9 had a close relation with PI3K/AKT/mTOR pathway. In functional experiments, peptide ARHGEF9 could suppress the protein expressions of p-PIK3K, p-AKT and p-mTOR, while IGF-1 could reverse this effect.

Conclusion: This study identifies 6 new prognostic biomarkers for glioma patients. Among them, peptide ARHGEF9 gene is an inhibitory gene functioning by targeting PI3K/AKT/mTOR pathway.

Abstract Image

查看原文本刊更多论文

多肽 ARHGEF9 通过 PI3K/AKT/mTOR 通路抑制胶质瘤进展

背景：胶质瘤是人类脑神经系统中最常见的恶性肿瘤。多肽是由α-氨基酸的肽键形成的化合物，多肽药物的开发已广泛应用于多个领域。我们计划研究胶质瘤中具有临床价值的多肽：方法：基于公共数据库，我们锁定了胶质瘤差异表达基因（DEGs）和与胶质瘤预后相关的多肽基因之间的共同基因。然后，通过LASSO-Cox分析、预后风险模型和提名图分析这些共同基因，确定关键的预后肽基因和本研究的靶基因。接下来，通过生物信息学分析和功能实验探讨了靶基因在胶质瘤中的作用机制：结果：我们共获得了 26 个重叠基因用于后续研究。随后，我们得到了6个独立的预后因子（REPIN1、PSD3、RDX、CDK4、FANCI和ARHGEF9），并将其应用于构建预后提名图，ARHGEF9是本研究的靶基因。接着，研究发现多肽 ARHGEF9 可抑制胶质瘤细胞的发展。通过斯皮尔曼相关分析，ARHGEF9与PI3K/AKT/mTOR通路关系密切。在功能实验中，多肽ARHGEF9能抑制p-PIK3K、p-AKT和p-mTOR的蛋白表达，而IGF-1则能逆转这种效应：结论：这项研究为胶质瘤患者确定了6种新的预后生物标志物。结论：本研究发现了胶质瘤患者的6个新预后生物标志物，其中多肽ARHGEF9基因是通过靶向PI3K/AKT/mTOR通路发挥作用的抑制基因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Disease Markers 医学-病理学

自引率

0.00%

发文量

792

审稿时长

6-12 weeks

期刊介绍： Disease Markers is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the identification of disease markers, the elucidation of their role and mechanism, as well as their application in the prognosis, diagnosis and treatment of diseases.